The other listed mechanisms refer to non-DOAC medication classes. Vitamin K antagonists (VKAs) include warfarin. Although a DOAC agent may directly inhibit thrombin, other agents work to indirectly inhibit thrombin. Heparin works to first activate antithrombin III, which then inhibits thrombin and FXa, among other enzymes. Experimental agents work to lyse or deplete fibrinogen; however, no such agents are currently approved for use in stroke prevention in patients with AF.
Learn more about the mechanism of action of DOAC agents.
Medscape © 2020 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Sandeep K. Goyal. Fast Five Quiz: Direct Oral Anticoagulant Therapy for Atrial Fibrillation - Medscape - Apr 02, 2020.